相关临床试验
53
32 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2001
进行中（未招募）
32
60.4%
已完成
14
26.4%
终止
5
9.4%
Unknown
1
1.9%
撤回
1
1.9%
暂无批准数据
- DelveInsight's 2025 pipeline report reveals over 165 companies are developing 170+ investigational therapies for triple-negative breast cancer (TNBC), spanning from preclinical to Phase III trials. - Key emerging therapies include trilaciclib (G1 Therapeutics), olaparib (AstraZeneca), and patritumab deruxtecan (Daiichi Sankyo/Merck), with several receiving breakthrough therapy designations and showing promising clinical results. - Recent clinical milestones include Akeso's ivonescimab receiving breakthrough therapy designation from China's NMPA and Kazia Therapeutics reporting an immune-complete response in a stage IV TNBC patient treated with paxalisib combination therapy. - The TNBC therapeutics market is expected to experience substantial growth driven by rising incidence rates, improved diagnostics, increased awareness, and the anticipated introduction of novel treatment options.
- Over 22 pharmaceutical companies are actively developing 25+ pipeline drugs for basal cell neoplasms, the most common type of skin cancer characterized by slow growth and low metastatic potential. - Recent clinical milestones include Senhwa Biosciences completing Phase I trials for Silmitasertib with positive survival outcomes, and multiple companies reporting positive Phase II results for their respective candidates. - Leading late-stage candidates include Sol-Gel Technologies' Patidegib, a first-in-class topical hedgehog pathway inhibitor targeting Gorlin Syndrome and basal cell carcinomas. - The pipeline features diverse mechanisms of action including SMO protein inhibitors, tyrosine kinase inhibitors, and casein kinase II inhibitors, addressing the growing demand driven by rising UV exposure and aging populations.
- DelveInsight's 2025 report reveals over 165 companies are developing 170+ pipeline therapies for triple-negative breast cancer, driven by rising disease prevalence and growing research investments. - Recent clinical milestones include Cardiff Oncology's positive Phase 1b data for onvansertib plus paclitaxel, Akeso's breakthrough therapy designation for ivonescimab combination, and multiple Phase III studies initiated by AstraZeneca and others. - Leading pipeline candidates include trilaciclib (G1 Therapeutics), olaparib (AstraZeneca), and patritumab deruxtecan (Daiichi Sankyo/Merck), representing diverse therapeutic approaches from CDK4/6 inhibitors to antibody-drug conjugates. - The TNBC therapeutics market is expected to undergo substantial growth due to improved diagnostics, increased awareness, higher healthcare spending, and anticipated launches of innovative treatments.
